The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women
- 3k Downloads
BMD and clinical risk factors predict hip and other osteoporotic fractures. The combination of clinical risk factors and BMD provide higher specificity and sensitivity than either alone.
Introduction and hypotheses
To develop a risk assessment tool based on clinical risk factors (CRFs) with and without BMD.
Nine population-based studies were studied in which BMD and CRFs were documented at baseline. Poisson regression models were developed for hip fracture and other osteoporotic fractures, with and without hip BMD. Fracture risk was expressed as gradient of risk (GR, risk ratio/SD change in risk score).
CRFs alone predicted hip fracture with a GR of 2.1/SD at the age of 50 years and decreased with age. The use of BMD alone provided a higher GR (3.7/SD), and was improved further with the combined use of CRFs and BMD (4.2/SD). For other osteoporotic fractures, the GRs were lower than for hip fracture. The GR with CRFs alone was 1.4/SD at the age of 50 years, similar to that provided by BMD (GR = 1.4/SD) and was not markedly increased by the combination (GR = 1.4/SD). The performance characteristics of clinical risk factors with and without BMD were validated in eleven independent population-based cohorts.
The models developed provide the basis for the integrated use of validated clinical risk factors in men and women to aid in fracture risk prediction.
KeywordsBone mineral density Hip fracture Meta-analysis Osteoporotic fracture Risk assessment
We are grateful to the principal investigators of the cohorts studied and the investigators of the Women’s Health Initiative (http://www.whi.org/about). We would like to thank the Alliance for Better Bone Health, Hologic, IGEA, Lilly, Lunar, Merck Research Laboratories, Novartis, Pfizer, Roche, Servier and Wyeth for their unrestricted support of this work. We are also grateful to the EU (FP3/5), the International Osteoporosis Foundation, the International Society for Clinical Densitometry and the National Osteoporosis Foundation for supporting this study.
- 2.Committee for Proprietary Medicinal Products (CPMP) (2001) Note for guidance on postmenopausal osteoporosis in women. European Agency for the Evaluation of Medicinal Products, London (CPMP/EWP/552/95 rev 1)Google Scholar
- 3.Food and Drug Administration (1994) Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis. Division of Metabolism and Endocrine Drug Products, Rockville, MDGoogle Scholar
- 4.Royal College of Physicians (1999) Clinical Guidelines for strategies to prevent and treat osteoporosis. Royal College of Physicians, LondonGoogle Scholar
- 6.National Osteoporosis Foundation (NOF) (2003) Physician’s Guide to prevention and treatment of osteoporosis. National Osteoporosis Foundation, Washington, DCGoogle Scholar
- 7.European Community (1998) Report on osteoporosis in the European Community. EC, StrasbourgGoogle Scholar
- 8.Brown JP, Josse RG (2002) Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Can Med Assoc J 167(10 Suppl):S1–S34Google Scholar
- 13.Kanis JA, Johnell O, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton III LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382PubMedCrossRefGoogle Scholar
- 14.Johnell O, Kanis JA, Oden A, Johansson H, De Laet C, Delmas P, Eisman JA, Fujiwara S, Kroger H, Mellstrom D, Meunier P, Melton LJ III, O’Neill T, Pols H, Reeve J, Silman A, Tenenhouse A (2005) Predictive value of bone mineral density for hip and other fractures. J Bone Miner Res 20:1185–1194PubMedCrossRefGoogle Scholar
- 15.De Laet C, Kanis JA, Oden A (2005) Body mass index as a prediction of fracture risk. A meta-analysis. Osteoporos Int, in pressGoogle Scholar
- 17.Kanis JA, Johansson H, Oden A, De Laet C, Johnell O, Eisman JA, McCloskey E, Mellstrom D, Pols H, Reeve J, Silman A, Tenenhouse A (2005) A meta-analysis of milk intake and fracture risk: low utility for case finding. Osteoporos Int, in pressGoogle Scholar
- 23.Felsenberg D, Silman AJ, Lunt M, Ambrecht G, Ismail AA, Finn JD, Cockerill WC, Banzer D, Benevolenskaya LI, Bhalla A, Bruges Armas J, Cannata JB, Cooper C, Dequeker J, Eastell R, Ershova O, Felsch B, Gowin W, Havelka S, Hoszowski K, Jajic I, Janot J, Johnell O, Kanis JA, Kragl G, Lopez Vaz A, Lorenc R, Lyritis G, Masaryk P, Matthis C, Miazgowski T, Parisi G, Pols HAP, Poor G, Raspe HH, Reid DM, Reisinger W, Scheidt-Nave C, Stepan J, Todd C, Weber K, Woolf AD, Reeve J, O’Neill TW (2002) Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study Epos. J Bone Miner Res 17:716–724CrossRefGoogle Scholar
- 24.Ismail AA, Pye SR, Cockerill WC, Lunt M, Silman AJ, Reeve J, Banzer D, Benevolenskaya LI, Bhalla A, Bruges Armas J, Cannata JB, Cooper C, Delmas PD, Dequeker J, Dilsen G, Falch JA, Felsch B, Felsenberg D, Finn JD, Gennari C, Hoszowski K, Jajic I, Janott J, Johnell O, Kanis JA, Kragl G, Lopez Vaz A, Lorenc R, Lyritis G, Marchand F, Masaryk P, Matthis C, Miazgowski T, Naves-Diaz M, Pols HAP, Poor G, Rapado A, Raspe HH, Reid DM, Reisinger W, Scheidt-Nave C, Stepan J, Todd C, Weber K, Woolf AD, O’Neill TW (2002) Incidence of limb fracture across Europe: results from the European prospective osteoporosis study, EPOS. Osteoporosis Int 13:565–571CrossRefGoogle Scholar
- 25.Kreiger N, Tenenhouse A, Joseph L et al (1999) The canadian multicentre osteoporosis study CaMos: background, rationale, methods. Can J Ageing 18:376–387Google Scholar
- 29.McCloskey EV, Beneton M, Charlesworth D, Kayan K, Detakats D, Dey A, OrgeeJ, Ashford R, Forster M, Cliffe J, Kersh L, Brazier J, Nichol J, Aropuu S, Jalava T, Kanis JA (2006) Clodronate reduces the incidence of fractures in community dwelling elderly women unselected for osteoporosis-results of a double blind, placebo controlled randomised study. J Bone Miner Res 22:135–141CrossRefGoogle Scholar
- 31.Svanborg A (1977) 70 year old people in Gothenburg. A population study in an industrialised Swedish city ii. Journal Presentation of Social and Medical Conditions. Acta Medica Scand 611(suppl):5Google Scholar
- 36.Bagger YZ, Riis BJ, Alexandersen P, Tanko LB, Christiansen C (2001) Risk factors for development of osteoporosis and cardiovascular disease in postmenopausal Danish women: the PERF study. J Bone Miner Res 16:396Google Scholar
- 38.Gluer CC, Eastell R, Reid DM, Felsenberg D, Roux C, Barkmann R, Timm W, Bleak T, Almbrecht G, Stewart A, Clowes J, Thomasins FE, Kolta S (2004) Association of five quantitative ultrasound devices and bone densitometry with osteoporotic fractures in a population-based source : the OPUS study. J Bone Miner Res 19:782–793PubMedCrossRefGoogle Scholar
- 41.Sanders KM, Pasco JA, Ugoni A, Nicholson GC, Seeman E, Martin TJ, Skovic B, Panahi S, Kotowicz MA (1998) The exclusion of high trauma fractures may underestimate the prevalence of bone fragility fractures in the community. The Geelong Osteoporosis Study. J Bone Miner Res 13:1337–1342PubMedCrossRefGoogle Scholar
- 47.Edgeworth FY (1905) The law of error. Proc Cambr Philosoph Soc 20:36Google Scholar
- 52.Nevitt MC, Cummings SR, Stone KL et al (1997) Risk factors for a first incident radiographic vertebral fracture in women ≥ years of age: The Study of Osteoporotic fracturesGoogle Scholar
- 53.Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 312:1254–1259Google Scholar
- 67.Van Staa T-P, Geusens P, Pols HAP, De Laet C, Leufkens HCM, Cooper C (2005) A simple score for estimating the long-term risk of fracture in patients using oral glucocorticoids. Q J Med 98:191–198Google Scholar
- 71.McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, Hip Intervention Program Study Group (2001) Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 344:333–340PubMedCrossRefGoogle Scholar
- 72.Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S, Thamsborg G, Liberman UA, Delmas PD, Maliee MP, Czachur M, Daifotis AG (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-induced Osteoporosis Intervention Study Group. N Engl J Med 339:292–299PubMedCrossRefGoogle Scholar
- 73.Adachi JD, Saag KG, Delmas PD, Liberman UA, Emkey RD, Seeman E, Lane NE, Kaufman JM, Poubelle PE, Hawkins F, Correa-Rotter R, Menkes CJ, Rodriguez-Portales JA, Schnitzer TJ, Block JA, Wing J, McIlwain J III, Westhovens R, Brown J, Melo-Gomes JA, Gruber BL, Yanover MJ, Leite MO, Sammoski KG, Nevitt MC, Sharp JT, Malice MP, Dumortier T, Czachur M, Carofano W, Daifotis A (2001) Two year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomised, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202–211PubMedCrossRefGoogle Scholar
- 77.Roux C, Reginster JY, Fechtenbaum J, Kolta S, Sawieki A, Tulassay Z, Luisetto G, Padrino JM, Doyle D, Prince R, Fardellone P, Sorensen OH, Meunier PJ (2006) Vertebral fracture risk reduction with strontium ranelate in women with post-menopausal osteoporosis is independent of baseline risk factors. J Bone Miner Res, in pressGoogle Scholar